Wild-type (senile) amyloidosis other diagnostic studies: Difference between revisions
Aditya Ganti (talk | contribs) |
|||
(9 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Wild-type (senile) amyloidosis}} | {{Wild-type (senile) amyloidosis}} | ||
{{CMG}} | {{CMG}}{{AE}}{{ADG}} | ||
==Overview== | ==Overview== | ||
Other [[Diagnosis|diagnostic]] studies that help in [[Diagnosis|diagnosing]] wild-type (senile) amyloidosis include [[Histopathology|histopathological]] [[analysis]] and [[genetic testing]]. | |||
==Other Diagnostic Studies== | ==Other Diagnostic Studies== | ||
Other [[Diagnosis|diagnostic]] studies that help in [[Diagnosis|diagnosing]] wild-type (senile) amyloidosis include [[Histopathology|histopathological]] [[analysis]] and [[genetic testing]].<ref name="pmid23964755">{{cite journal |vauthors=Damy T, Deux JF, Moutereau S, Guendouz S, Mohty D, Rappeneau S, Guellich A, Hittinger L, Loric S, Lefaucheur JP, Plante-Bordeneuve V |title=Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis |journal=Amyloid |volume=20 |issue=4 |pages=212–20 |date=December 2013 |pmid=23964755 |doi=10.3109/13506129.2013.825240 |url=}}</ref> | |||
=== | |||
< | |||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ | ||
! | ! colspan="2" |Other Diagnostic Studies | ||
| | |||
|- | |- | ||
!Histopathological analysis | |||
| | | | ||
* EMB with histopathology remains the gold standard for diagnosis of cardiac amyloidosis. | *[[Endomyocardial biopsy|Endomyocardial biopsy (EMB)]] with [[histopathology]] remains the [[Gold standard (test)|gold standard]] for [[diagnosis]] of cardiac amyloidosis. | ||
* Histopathology demonstrates deposition of amorphous deposits of amyloid fibrils in the heart. | *[[Histopathology]] demonstrates deposition of amorphous deposits of [[amyloid]] fibrils in the [[heart]]. | ||
* The binding of Congo red stain to the deposited amyloid fibrils leads to characteristic apple-green birefringence under polarized light microscopy and an intense yellow-green fluorescence is seen when binding to thioflavin. | * The binding of [[Congo red]] [[stain]] to the deposited [[amyloid]] fibrils leads to characteristic apple-green [[birefringence]] under polarized [[light microscopy]] and an intense yellow-green [[fluorescence]] is seen when binding to [[thioflavin]]. | ||
* Precursor protein identification can be accomplished by immunohistochemistry, electron microscopy, or mass spectrometry (preferred), depending upon institutional expertise. | * Precursor [[protein]] identification can be accomplished by [[immunohistochemistry]], [[Electron microscope|electron microscopy]], or [[mass spectrometry]] (preferred), depending upon institutional expertise. | ||
* Adjunctive laboratory tests to rule out AL include assaying for other organ dysfunction (e.g., proteinuria, alkaline phosphatase) and directly measuring the circulating light chains in plasma. | * Adjunctive [[laboratory]] [[Test|tests]] to rule out AL include assaying for other [[Organ (anatomy)|organ]] dysfunction (e.g., [[proteinuria]], [[alkaline phosphatase]]) and directly measuring the circulating [[Light chain|light chains]] in [[Blood plasma|plasma]]. | ||
* EMB is associated with risks of complications such as | *[[Endomyocardial biopsy|EMB]] is associated with risks of [[Complication (medicine)|complications]] such as: | ||
** Ventricular free-wall perforation | **[[Ventricle (heart)|Ventricular]] free-wall [[perforation]] | ||
** Arrhythmia | **[[Cardiac arrhythmia|Arrhythmia]] | ||
** Conduction abnormalities | **[[Electrical conduction system of the heart|Conduction]] abnormalities | ||
|- | |- | ||
!Genetic testing | |||
| | | | ||
* DNA sequencing for the transthyretin gene | *[[DNA]] sequencing for the [[transthyretin]] [[gene]] | ||
* Absence of amino acid sequence abnormalities by mass spectrometry is consistent with | * Absence of [[amino acid]] sequence abnormalities by [[mass spectrometry]] is consistent with wild-type (senile) amyloidosis | ||
* Presence of a pathologic mutation | * Presence of a [[Pathology|pathologic]] [[mutation]] | ||
** Predict sites of organ involvement | ** Predict sites of [[Organ (anatomy)|organ]] involvement | ||
** Family history | **[[Family history]] | ||
|} | |} | ||
Latest revision as of 19:13, 20 December 2019
Wild-type (senile) amyloidosis Microchapters |
Differentiating Wild-type (senile) amyloidosis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Wild-type (senile) amyloidosis other diagnostic studies On the Web |
American Roentgen Ray Society Images of Wild-type (senile) amyloidosis other diagnostic studies |
FDA on Wild-type (senile) amyloidosis other diagnostic studies |
CDC on Wild-type (senile) amyloidosis other diagnostic studies |
Wild-type (senile) amyloidosis other diagnostic studies in the news |
Blogs on Wild-type (senile) amyloidosis other diagnostic studies |
Risk calculators and risk factors for Wild-type (senile) amyloidosis other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
Other diagnostic studies that help in diagnosing wild-type (senile) amyloidosis include histopathological analysis and genetic testing.
Other Diagnostic Studies
Other diagnostic studies that help in diagnosing wild-type (senile) amyloidosis include histopathological analysis and genetic testing.[1]
Other Diagnostic Studies | |
---|---|
Histopathological analysis |
|
Genetic testing |
|
References
- ↑ Damy T, Deux JF, Moutereau S, Guendouz S, Mohty D, Rappeneau S, Guellich A, Hittinger L, Loric S, Lefaucheur JP, Plante-Bordeneuve V (December 2013). "Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis". Amyloid. 20 (4): 212–20. doi:10.3109/13506129.2013.825240. PMID 23964755.